Rema Raman
Cited by
Cited by
Comprehensive molecular characterization of gastric adenocarcinoma
AJ Bass, V Thorsson, I Shmulevich, SM Reynolds, M Miller, B Bernard, ...
Nature 513 (7517), 202, 2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ...
New England Journal of Medicine 370 (4), 311-321, 2014
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease
GB Stokin, C Lillo, TL Falzone, RG Brusch, E Rockenstein, SL Mount, ...
Science 307 (5713), 1282-1288, 2005
A phase 3 trial of semagacestat for treatment of Alzheimer's disease
RS Doody, R Raman, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, ...
New England Journal of Medicine 369 (4), 341-350, 2013
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
JF Quinn, R Raman, RG Thomas, K Yurko-Mauro, EB Nelson, C Van Dyck, ...
Jama 304 (17), 1903-1911, 2010
Giant cell arteritis: validity and reliability of various diagnostic criteria
SS Hayreh, PA Podhajsky, R Raman, B Zimmerman
American journal of ophthalmology 123 (3), 285-296, 1997
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
RS Turner, RG Thomas, S Craft, CH Van Dyck, J Mintzer, BA Reynolds, ...
Neurology 85 (16), 1383-1391, 2015
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L) final results
TM Hemmen, R Raman, KZ Guluma, BC Meyer, JA Gomes, S Cruz-Flores, ...
Stroke 41 (10), 2265-2270, 2010
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans
PS Aisen, RC Petersen, MC Donohue, A Gamst, R Raman, RG Thomas, ...
Alzheimer's & Dementia 6 (3), 239-246, 2010
Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease
AS Fleisher, R Raman, ER Siemers, L Becerra, CM Clark, RA Dean, ...
Archives of neurology 65 (8), 1031-1038, 2008
Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study
BC Meyer, R Raman, T Hemmen, R Obler, JA Zivin, R Rao, RG Thomas, ...
The Lancet Neurology 7 (9), 787-795, 2008
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline
MC Donohue, RA Sperling, DP Salmon, DM Rentz, R Raman, ...
JAMA neurology 71 (8), 961-970, 2014
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism
R Kurlan, J Cummings, R Raman, L Thal
Neurology 68 (17), 1356-1363, 2007
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease
EJ Pappert, CG Goetz, FG Niederman, R Raman, S Leurgans
Movement disorders: official journal of the Movement Disorder Society 14 (1 …, 1999
Effect of head impacts on diffusivity measures in a cohort of collegiate contact sport athletes
TW McAllister, JC Ford, LA Flashman, A Maerlender, RM Greenwald, ...
Neurology 82 (1), 63-69, 2014
Poor visual discrimination and visual hallucinations in Parkinson's disease.
NJ Diederich, CG Goetz, R Raman, EJ Pappert, S Leurgans, V Piery
Clinical neuropharmacology 21 (5), 289-295, 1998
Prospective longitudinal assessment of hallucinations in Parkinson’s disease
CG Goetz, S Leurgans, EJ Pappert, R Raman, AB Stemer
Neurology 57 (11), 2078-2082, 2001
Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab study group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease
RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, ...
N Engl J Med 370 (4), 311-321, 2014
Decreased color discrimination and contrast sensitivity in Parkinson’s disease
V Pieri, NJ Diederich, R Raman, CG Goetz
Journal of the neurological sciences 172 (1), 7-11, 2000
Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease
PN Tariot, LS Schneider, J Cummings, RG Thomas, R Raman, ...
Archives of General Psychiatry 68 (8), 853-861, 2011
The system can't perform the operation now. Try again later.
Articles 1–20